A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

Acalabrutinib, a Bruton tyrosine kinase inhibitor, demonstrated greater selectivity and improved safety versus ibrutinib in a head‐to‐head trial in relapsed/refractory (R/R) chronic lymphocytic leukaemia. In the R/R marginal zone lymphoma (MZL) cohort (phase 2) of a phase 1b/2 trial (NCT02180711), 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Strati, Paolo, Coleman, Morton, Champion, Rebecca, Ma, Shuo, Patti, Caterina, Levy, Moshe Y., Lossos, Izidore S., Geethakumari, Praveen Ramakrishnan, Lam, Selay, Calvo, Roser, Higgins, Kara, Budde, Lihua E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796553/
https://www.ncbi.nlm.nih.gov/pubmed/35861370
http://dx.doi.org/10.1111/bjh.18368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796553/
https://www.ncbi.nlm.nih.gov/pubmed/35861370
http://dx.doi.org/10.1111/bjh.18368

Ejemplares similares